Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | ACHE | P22303 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12573087 | 0.85 | ACHE (0.55) | ALDH1A1KDM4EKMT2AACHESMN1; SMN2 | |
| SCHEMBL747460 | 0.84 | SMN1; SMN2 (0.57) | ALDH1A1KDM4EKMT2AACHESMN1; SMN2 | |
| SCHEMBL1503329 | 0.84 | ACHE (0.54) | ALDH1A1KDM4EACHESMN1; SMN2HPGD | |
| SCHEMBL16162264 | 0.82 | MEN1 (0.55) | ALDH1A1KDM4EKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL1033654 | 0.81 | ALDH1A1 (0.53) | ALDH1A1KDM4EKMT2AACHESMN1; SMN2 | |
| SCHEMBL11284051 | 0.81 | ACHE (0.57) | ALDH1A1KDM4EACHEBCHEOPRM1 | |
| Hydrochloric Acid SCHEMBL11273784 | 0.81 | ACHE (0.56) | ALDH1A1KDM4EACHEBCHEOPRM1 | |
| SCHEMBL1039110 | 0.79 | SIGMAR1 (0.51) | ALDH1A1KDM4EKMT2AACHESMN1; SMN2 | |
| SCHEMBL11271213 | 0.77 | ACHE (0.58) | ALDH1A1KDM4EKMT2AACHESMN1; SMN2 | |
| SCHEMBL1035892 | 0.77 | SLC2A1 (0.49) | ALDH1A1ACHEHSD17B2BCHESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280955-B1 | CRYSTALLINE FORM OF 6-Ý(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL¨PYRIDAZIN-3-AMINE | ALBANY MOLECULAR RES INC (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-2280955-B1 | CRYSTALLINE FORM OF 6-Ý(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL¨PYRIDAZIN-3-AMINE | ALBANY MOLECULAR RES INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9498476-B2 | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9498476-B2 | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150366864-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | CURIA GLOBAL, INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150366864-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | CURIA GLOBAL, INC. | 2015-12-24 | — | — | US | disclosed |
| US-9156812-B2 | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156812-B2 | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150191494-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | ALBANY MOLECULAR RESEARCH, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20150191494-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | ALBANY MOLECULAR RESEARCH, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20130060027-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130060027-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-07 | — | — | US | disclosed |
| US-20110160220-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | Bristol-Myers Squibb Company and Albany Molecular Research, Inc. | 2011-06-30 | — | — | US | disclosed |
| US-20110160220-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | Bristol-Myers Squibb Company and Albany Molecular Research, Inc. | 2011-06-30 | — | — | US | disclosed |
| US-20110077400-A1 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | Bristol-Myers Squibb Company and Albany Molecular Research, Inc | 2011-03-31 | — | — | US | disclosed |
| US-20110077400-A1 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | Bristol-Myers Squibb Company and Albany Molecular Research, Inc | 2011-03-31 | — | — | US | disclosed |
| EP-2280956-A2 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | Bristol-Myers Squibb Company (US) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009149258-A2 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009149259-A2 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009149259-A2 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366864-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | HTR2C, SYNCRIP, SFPQ | ALDH1A1 2680/4885KDM4E 734/4885KMT2A 1172/4885 |
| US-20130060027-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | FARS2, TPH1, COQ8A | ALDH1A1 1069/4885KDM4E 1814/4885KMT2A 1412/4885 |
| US-20150191494-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | FARS2, TPH1, COQ8A | ALDH1A1 1069/4885KDM4E 1814/4885KMT2A 1412/4885 |
| US-20110077400-A1 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | HTR2C, HTR3B, TPH2 | ALDH1A1 1784/4885KDM4E 1380/4885KMT2A 1371/4885 |
| US-20110160220-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | HTR2C, SYNCRIP, SFPQ | ALDH1A1 2680/4885KDM4E 734/4885KMT2A 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.